SHR8735

Atridia Pty Ltd. · Phase 1 active Small molecule

At a glance

Generic name	SHR8735
Sponsor	Atridia Pty Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Hetrombopag in Secondary Prevention of XPO-1 Inhibitor-induced Thrombocytopenia in Lymphoma (PHASE2)
A Trial of SHR8735 in Healthy Subjects (PHASE1)
A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SHR8735 CI brief — competitive landscape report
SHR8735 updates RSS · CI watch RSS
Atridia Pty Ltd. portfolio CI